 | | Vol. 15.09 – 22 March, 2024 |
| |
|
|
| The authors showed that dihydroorotate dehydrogenase (DHODH), an enzyme crucial in the pyrimidine biosynthesis pathway, was a promising therapeutic target for CRPC. The transcript levels of DHODH were significantly elevated in prostate tumors.
[Oncogene] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists discovered that caffeic acid phenethyl ester could repress the expression and downstream signaling of AR-V7 in prostate cancer cells.
[Oncogene] |
|
|
|
| Sleep deprivation (SD) was utilized to establish a mouse model of insufficient sleep in a special device. Prostatitis was observed at different time points post-SD.
[Cell Communication and Signaling] |
|
|
|
| With in vivo and in vitro ubiquitination assays, OUT domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) was shown to block ubiquitin transfer to YTH domain-containing family protein 2 (YTHDF2) independent of its deubiquitinase activity.
[Journal of Biological Chemistry] |
|
|
|
| Investigators integrated DNA methylation, RNA-seq, and copy number alterations datasets from The Cancer Genome Atlas, focusing on prostate adenocarcinoma, and employed weighted gene co-expression network analysis.
[Epigenetics & Chromatin] |
|
|
|
| Scientists investigated the role of carnitine palmitoyltransferase 1A (CPT1A), which was a succinyltransferase in the progression of prostate cancer. CCK-8 was used to detect the cell viability.
[Cancer Biology & Therapy] |
|  |
|
|
|
| The authors discuss prostate carcinoma cell lines and offer a comprehensive review intended to scrutinize the associations and interactions between transposable elements and genes.
[Journal of Cellular Biochemistry] |
|
|
|
|
| The Prostate Cancer Foundation (PCF) announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research.
[The Prostate Cancer Foundation] |
|
|
|
| A prostate cancer research team including Drs. Roseline Godbout, Adam Kinnaird, and Ron Moore have been awarded a $1.25 million, four-year Alberta Cancer Foundation “Game Changer Grant” to investigate the link between fat metabolism and prostate cancer progression.
[University of Alberta] |
|
|
|
|
| April 7 – 10, 2024
San Diego, California, United States |
|
|
|
|
|
| | Columbia University – New York City, New York, United States |
|
|
|
| | Princess Margaret Cancer Centre – Toronto, Ontario, Canada |
|
|
|
| | Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
| | The Henry M. Jackson Foundation – Bethesda, Maryland, United States |
|
|
|
| | UC Davis – Davis, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
